Asunto(s)
Analgésicos/uso terapéutico , Equimosis/etiología , Trastornos Migrañosos/complicaciones , Equimosis/tratamiento farmacológico , Equimosis/fisiopatología , Cara , Femenino , Humanos , Trastornos Migrañosos/tratamiento farmacológico , Trastornos Migrañosos/fisiopatología , Recurrencia , Piel/irrigación sanguínea , Piel/inervación , Resultado del Tratamiento , Nervio Trigémino/fisiopatología , Adulto JovenAsunto(s)
Antiinfecciosos/uso terapéutico , Dermatitis Alérgica por Contacto/tratamiento farmacológico , Dermatitis Alérgica por Contacto/epidemiología , Tiazoles/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pruebas del Parche , Estudios Retrospectivos , España/epidemiología , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVE: Although dermatology has traditionally been practiced through outpatient consultation, hospitalized patients often have dermatologic problems. The aim of this study was to describe and quantify the volume of interdepartmental consultation of the dermatology department of Hospital Universitario Virgen del Rocío. MATERIAL AND METHODS: In this year-long prospective observational cohort study of 429 patients we used a specific data collection form to record information on consultations for patients admitted between July 2010 and June 2011. RESULTS: The 429 consultations over the 12 months of study accounted for 1.56% of all first consultations with a dermatologist during the period. A mean of 1.75 new patients were attended each day. The mean (SD) age of the patients was 52.63 (19) years, and the ratio of men to women was 1.21. Immunocompromised patients accounted for more than a third of the cohort. The medical specialties consulting most often were internal medicine (n=115) and hematology (n=66). The most frequent diagnoses were inflammatory skin conditions (36.2%) and infectious skin diseases (26.5%). DISCUSSION AND CONCLUSIONS: To date, the role of interdepartmental consultation in dermatology has been little studied. Our results suggest that dermatology plays a fundamental role within the hospital. We have identified the most common skin problems in hospitalized patients and their clinical course.
Asunto(s)
Atención Ambulatoria , Derivación y Consulta/estadística & datos numéricos , Enfermedades de la Piel , Centros de Atención Terciaria , Estudios de Cohortes , Dermatología , Femenino , Humanos , Pacientes Internos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/terapia , EspañaRESUMEN
BACKGROUND: There are several therapeutic options for infantile haemangiomas (IH). Propranolol is used according to a pivotal trial. We aimed to describe the characteristics of IH in clinical practice, including the therapies used, and to compare the characteristics of patients treated with propranolol with those of the trial to assess its external validity. METHODS: Consecutive patients attending 12 Spanish hospitals from June 2016 to October 2019 were included (n=601). RESULTS: The mean age was 3.9 (SD:1.9) months, with a 2:1 female-to-male ratio. Most IHs were localized (82%, 495), superficial (64%, 383) and located in the face (25%, 157) and trunk (31%, 188). Median size was 17 (IR: 10-30) x 12 (IR: 7-20) mm. Complications were found in 16 (3%) patients. Treatment was initiated for 52% (311). Most patients received timolol (76%, 237); propranolol was reserved for complications or high-risk IHs. Aesthetic impairment was the main reason for starting therapy (64%, 199). Several characteristics of the patients and IHs treated with propranolol are similar to those of the pivotal clinical trial, but 1/3 of IHs did not reach the minimum diameter to meet the inclusion criteria, and important prognostic information was not reported. CONCLUSIONS: As most patients receive treatment for aesthetic impairment, there is a need to better understand the aesthetic results of therapies and to increase evidence on the use of timolol, which is currently the most common therapy. Propranolol is being used in a population generally similar to that of the trial; however, this statement cannot be definitely confirmed.
Asunto(s)
Adenoma/genética , Carcinoma/genética , Inestabilidad de Microsatélites , Síndrome de Muir-Torre/genética , Proteína 2 Homóloga a MutS/genética , Neoplasias de las Glándulas Sebáceas/genética , Colectomía/métodos , Neoplasias del Colon/genética , Neoplasias del Colon/cirugía , Pólipos del Colon/genética , Pólipos del Colon/cirugía , ADN de Neoplasias/genética , Exones/genética , Salud de la Familia , Pruebas Genéticas , Humanos , Hiperplasia , Masculino , Persona de Mediana Edad , Mutación Missense , Glándulas Sebáceas/patologíaAsunto(s)
Inmunodeficiencia Variable Común/patología , Enfermedad Granulomatosa Crónica/patología , Trastornos Necrobióticos/patología , Piel/patología , Adulto , Antiinflamatorios no Esteroideos/administración & dosificación , Anticuerpos Monoclonales/administración & dosificación , Inmunodeficiencia Variable Común/complicaciones , Inmunodeficiencia Variable Común/tratamiento farmacológico , Diagnóstico Diferencial , Etanercept , Femenino , Enfermedad Granulomatosa Crónica/tratamiento farmacológico , Enfermedad Granulomatosa Crónica/etiología , Humanos , Inmunoglobulina G/administración & dosificación , Inmunoglobulina G/sangre , Inmunoterapia/métodos , Inmunoterapia/tendencias , Infliximab , Trastornos Necrobióticos/tratamiento farmacológico , Trastornos Necrobióticos/etiología , Receptores del Factor de Necrosis Tumoral/administración & dosificación , Factor de Necrosis Tumoral alfa/antagonistas & inhibidoresRESUMEN
No disponible